Vatera Healthcare Partners

ImmusanT, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing therapies and diagnostics for celiac disease. Founded in 2010, the company aims to restore tolerance to gluten in patients with this autoimmune disorder. Its primary product, Nexvax2, is a therapeutic vaccine designed to treat, prevent, and diagnose celiac disease. Additionally, ImmusanT has developed a functional T-cell test that aids in diagnosing and monitoring the maintenance of immune tolerance in patients undergoing peptide-based therapy. By leveraging advancements in immunology, ImmusanT seeks to enhance the management of celiac disease and potentially other autoimmune conditions.

Melinta Therapeutics, Inc. is a commercial-stage pharmaceutical company based in Morristown, New Jersey, specializing in the discovery, development, and commercialization of anti-infective therapies for bacterial infections in North America. The company offers a range of antibiotics, including Baxdela, Vabomere, Orbactiv, and Minocin, targeting various serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSIs) and gram-negative infections. Melinta is actively advancing its investigational antibiotic, delafloxacin, which is currently in Phase 3 development for ABSSSIs. Additionally, the company is engaged in research to develop new classes of antibiotics aimed at combating drug-resistant pathogens, particularly the ESKAPE group responsible for many hospital-acquired infections. Through its innovative approaches, Melinta Therapeutics addresses the urgent need for new therapies against drug-resistant infections, a critical public health challenge today.

ImmusanT, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing therapies and diagnostics for celiac disease. Founded in 2010, the company aims to restore tolerance to gluten in patients with this autoimmune disorder. Its primary product, Nexvax2, is a therapeutic vaccine designed to treat, prevent, and diagnose celiac disease. Additionally, ImmusanT has developed a functional T-cell test that aids in diagnosing and monitoring the maintenance of immune tolerance in patients undergoing peptide-based therapy. By leveraging advancements in immunology, ImmusanT seeks to enhance the management of celiac disease and potentially other autoimmune conditions.

Melinta Therapeutics, Inc. is a commercial-stage pharmaceutical company based in Morristown, New Jersey, specializing in the discovery, development, and commercialization of anti-infective therapies for bacterial infections in North America. The company offers a range of antibiotics, including Baxdela, Vabomere, Orbactiv, and Minocin, targeting various serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSIs) and gram-negative infections. Melinta is actively advancing its investigational antibiotic, delafloxacin, which is currently in Phase 3 development for ABSSSIs. Additionally, the company is engaged in research to develop new classes of antibiotics aimed at combating drug-resistant pathogens, particularly the ESKAPE group responsible for many hospital-acquired infections. Through its innovative approaches, Melinta Therapeutics addresses the urgent need for new therapies against drug-resistant infections, a critical public health challenge today.

Pearl Therapeutics is a privately held company dedicated to developing innovative therapies for prevalent respiratory diseases, including chronic obstructive pulmonary disease, rhinosinusitis, and asthma. The company specializes in creating unique dual and triple combination products, focusing on advanced inhaled therapies that are delivered through familiar metered dose inhalers. Led by a team of experienced professionals in respiratory product development, Pearl Therapeutics aims to provide patients and healthcare providers with alternatives that better address their needs. The company's goal is to enhance the safety and efficacy of existing respiratory treatments, ultimately improving clinical outcomes for individuals suffering from these conditions.

Melinta Therapeutics, Inc. is a commercial-stage pharmaceutical company based in Morristown, New Jersey, specializing in the discovery, development, and commercialization of anti-infective therapies for bacterial infections in North America. The company offers a range of antibiotics, including Baxdela, Vabomere, Orbactiv, and Minocin, targeting various serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSIs) and gram-negative infections. Melinta is actively advancing its investigational antibiotic, delafloxacin, which is currently in Phase 3 development for ABSSSIs. Additionally, the company is engaged in research to develop new classes of antibiotics aimed at combating drug-resistant pathogens, particularly the ESKAPE group responsible for many hospital-acquired infections. Through its innovative approaches, Melinta Therapeutics addresses the urgent need for new therapies against drug-resistant infections, a critical public health challenge today.

Pearl Therapeutics is a privately held company dedicated to developing innovative therapies for prevalent respiratory diseases, including chronic obstructive pulmonary disease, rhinosinusitis, and asthma. The company specializes in creating unique dual and triple combination products, focusing on advanced inhaled therapies that are delivered through familiar metered dose inhalers. Led by a team of experienced professionals in respiratory product development, Pearl Therapeutics aims to provide patients and healthcare providers with alternatives that better address their needs. The company's goal is to enhance the safety and efficacy of existing respiratory treatments, ultimately improving clinical outcomes for individuals suffering from these conditions.

Pearl Therapeutics is a privately held company dedicated to developing innovative therapies for prevalent respiratory diseases, including chronic obstructive pulmonary disease, rhinosinusitis, and asthma. The company specializes in creating unique dual and triple combination products, focusing on advanced inhaled therapies that are delivered through familiar metered dose inhalers. Led by a team of experienced professionals in respiratory product development, Pearl Therapeutics aims to provide patients and healthcare providers with alternatives that better address their needs. The company's goal is to enhance the safety and efficacy of existing respiratory treatments, ultimately improving clinical outcomes for individuals suffering from these conditions.

ImmusanT, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing therapies and diagnostics for celiac disease. Founded in 2010, the company aims to restore tolerance to gluten in patients with this autoimmune disorder. Its primary product, Nexvax2, is a therapeutic vaccine designed to treat, prevent, and diagnose celiac disease. Additionally, ImmusanT has developed a functional T-cell test that aids in diagnosing and monitoring the maintenance of immune tolerance in patients undergoing peptide-based therapy. By leveraging advancements in immunology, ImmusanT seeks to enhance the management of celiac disease and potentially other autoimmune conditions.

Pearl Therapeutics is a privately held company dedicated to developing innovative therapies for prevalent respiratory diseases, including chronic obstructive pulmonary disease, rhinosinusitis, and asthma. The company specializes in creating unique dual and triple combination products, focusing on advanced inhaled therapies that are delivered through familiar metered dose inhalers. Led by a team of experienced professionals in respiratory product development, Pearl Therapeutics aims to provide patients and healthcare providers with alternatives that better address their needs. The company's goal is to enhance the safety and efficacy of existing respiratory treatments, ultimately improving clinical outcomes for individuals suffering from these conditions.